These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 32064280)
21. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Dieterich M; Hartwig F; Stubert J; Klöcking S; Kundt G; Stengel B; Reimer T; Gerber B Breast; 2014 Aug; 23(4):346-51. PubMed ID: 24559611 [TBL] [Abstract][Full Text] [Related]
22. Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Cermik TF; Mavi A; Basu S; Alavi A Eur J Nucl Med Mol Imaging; 2008 Mar; 35(3):475-83. PubMed ID: 17957366 [TBL] [Abstract][Full Text] [Related]
23. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology? Basu S; Mavi A; Cermik T; Houseni M; Alavi A Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713 [TBL] [Abstract][Full Text] [Related]
24. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. Son SH; Lee SW; Jeong SY; Song BI; Chae YS; Ahn BC; Lee J AJR Am J Roentgenol; 2015 Oct; 205(4):878-85. PubMed ID: 26204115 [TBL] [Abstract][Full Text] [Related]
25. Clinicopathological characteristics and prognosis of triple-negative breast cancer invasive ductal carcinoma with ductal carcinoma in situ. Liu Y; Yu T J Cancer Res Clin Oncol; 2023 Oct; 149(13):11181-11191. PubMed ID: 37354223 [TBL] [Abstract][Full Text] [Related]
26. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Wong H; Lau S; Yau T; Cheung P; Epstein RJ Br J Cancer; 2010 Apr; 102(9):1391-6. PubMed ID: 20424617 [TBL] [Abstract][Full Text] [Related]
27. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma. Jung NY; Kim SH; Choi BB; Kim SH; Sung MS World J Surg Oncol; 2015 Mar; 13():113. PubMed ID: 25889560 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934 [TBL] [Abstract][Full Text] [Related]
29. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)? Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479 [TBL] [Abstract][Full Text] [Related]
30. The correlation of Qu YH; Long N; Ran C; Sun J Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [TBL] [Abstract][Full Text] [Related]
31. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer. Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047 [TBL] [Abstract][Full Text] [Related]
32. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer. Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383 [TBL] [Abstract][Full Text] [Related]
34. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857 [TBL] [Abstract][Full Text] [Related]
36. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study. Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458 [TBL] [Abstract][Full Text] [Related]
37. Contrast-Enhanced Mammographic Features of In Situ and Invasive Ductal Carcinoma Manifesting Microcalcifications Only: Help to Predict Underestimation? Cheung YC; Chen K; Yu CC; Ueng SH; Li CW; Chen SC Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503181 [TBL] [Abstract][Full Text] [Related]
38. p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. Mao XY; Fan CF; Zheng HC; Wei J; Yao F; Jin F J Exp Clin Cancer Res; 2010 Aug; 29(1):112. PubMed ID: 20712900 [TBL] [Abstract][Full Text] [Related]
39. Percentage change of primary tumor on 18F-FDG PET/CT as a prognostic factor for invasive ductal breast cancer with axillary lymph node metastasis: Comparison with MRI. Yoo J; Kim BS; Chung J; Yoon HJ Medicine (Baltimore); 2017 Aug; 96(31):e7657. PubMed ID: 28767583 [TBL] [Abstract][Full Text] [Related]
40. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH. Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]